Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
Researchers at Stanford and the European Molecular Biology Laboratory (EMBL) have discovered an improved embodiment of bacterial retron-based CRISPR gene editing in mammalian cells.
Researchers at Stanford previously described a method under Stanford Docket S17-020 for introducing a large number of gene edits in parallel, termed Multiplexed Accurate Genome Editing with Short, Trackable, Integrated Cellular barcodes (MAGESTIC).
Researchers in the Stanford Genome Technology Center have developed a robust, high-throughput, high-efficiency functional genomics platform to generate precisely edited genome variant libraries and then readily isolate and identify thousands of individual strains en masse